Literature DB >> 30190008

Orthostatic Hypotension: JACC State-of-the-Art Review.

Roy Freeman1, Ahmad R Abuzinadah2, Christopher Gibbons3, Pearl Jones4, Mitchell G Miglis5, Dong In Sinn5.   

Abstract

Neurogenic orthostatic hypotension is a highly prevalent and disabling feature of autonomic failure due to both peripheral and central neurodegenerative diseases. Community-based epidemiological studies have demonstrated a high morbidity and mortality associated with neurogenic orthostatic hypotension. It is due to impairment of baroreflex-mediated vasoconstriction of the skeletal muscle and splanchnic circulation and is caused by damage or dysfunction at central and/or peripheral sites in the baroreflex efferent pathway. Nonpharmacological and pharmacological interventions may be implemented to ameliorate the symptoms of orthostatic intolerance and improve quality of life. Many patients will be adequately treated by education, counseling, removal of hypotensive medications, and other nonpharmacological interventions, whereas more severely afflicted patients require pharmacological interventions. The first stage of pharmacological treatment involves repletion of central blood volume. If unsuccessful, this should be followed by treatment with sympathomimetic agents.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Keywords:  Parkinson disease; autonomic; baroreflex; blood pressure; diabetic neuropathies; sympathetic

Mesh:

Year:  2018        PMID: 30190008     DOI: 10.1016/j.jacc.2018.05.079

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  46 in total

1.  Neurogenic Orthostatic Hypotension. Lessons From Synucleinopathies.

Authors:  Juan Francisco Idiaquez; Juan Idiaquez; Juan Carlos Casar; Italo Biaggioni
Journal:  Am J Hypertens       Date:  2021-03-11       Impact factor: 2.689

2.  Editorial: The Magic of Spells.

Authors:  J E Morley
Journal:  J Nutr Health Aging       Date:  2020       Impact factor: 4.075

Review 3.  Management of Hypertension and Blood Pressure Dysregulation in Patients with Parkinson's Disease-a Systematic Review.

Authors:  Vasiliki Katsi; Ilias Papakonstantinou; Eirini Solomou; Alexios S Antonopoulos; Charalambos Vlachopoulos; Konstantinos Tsioufis
Journal:  Curr Hypertens Rep       Date:  2021-05-07       Impact factor: 5.369

4.  Orthostatic intolerance: a frailty marker for older adults.

Authors:  Arzu Okyar Baş; Merve Güner Oytun; Zeynep Kahyaoğlu; Süheyla Çöteli; Serdar Ceylan; İlker Boğa; Burcu Balam Doğu; Mustafa Cankurtaran; Meltem Gülhan Halil
Journal:  Eur Geriatr Med       Date:  2022-02-11       Impact factor: 1.710

Review 5.  Management of Orthostatic Hypotension in the Hospitalized Patient: A Narrative Review.

Authors:  Amr Wahba; Cyndya A Shibao; James A S Muldowney; Amanda Peltier; Ralf Habermann; Italo Biaggioni
Journal:  Am J Med       Date:  2021-08-18       Impact factor: 4.965

6.  Autonomic dysfunction in 'long COVID': rationale, physiology and management strategies.

Authors:  Melanie Dani; Andreas Dirksen; Patricia Taraborrelli; Miriam Torocastro; Dimitrios Panagopoulos; Richard Sutton; Phang Boon Lim
Journal:  Clin Med (Lond)       Date:  2020-11-26       Impact factor: 2.659

7.  Orthostatic Hypotension and Falls in Hospitalized Older Adults.

Authors:  Kathleen Schell; Denise Lyons; Barry Bodt
Journal:  Clin Nurs Res       Date:  2021-01-10       Impact factor: 2.075

Review 8.  Depression, antidepressants and fall risk: therapeutic dilemmas-a clinical review.

Authors:  E P van Poelgeest; A C Pronk; D Rhebergen; N van der Velde
Journal:  Eur Geriatr Med       Date:  2021-03-15       Impact factor: 1.710

Review 9.  Cardiovascular Disorders Mediated by Autonomic Nervous System Dysfunction.

Authors:  Pravin Khemani; Ali A Mehdirad
Journal:  Cardiol Rev       Date:  2020 Mar/Apr       Impact factor: 3.109

10.  The effects of caffeine in adults with neurogenic orthostatic hypotension: a systematic review.

Authors:  Jake Ryan Gibbon; James Frith
Journal:  Clin Auton Res       Date:  2021-06-18       Impact factor: 4.435

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.